These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038 [TBL] [Abstract][Full Text] [Related]
5. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259 [TBL] [Abstract][Full Text] [Related]
6. CD47 blockade as another immune checkpoint therapy for cancer. Vonderheide RH Nat Med; 2015 Oct; 21(10):1122-3. PubMed ID: 26444633 [No Abstract] [Full Text] [Related]
7. Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling. Xu MM; Pu Y; Han D; Shi Y; Cao X; Liang H; Chen X; Li XD; Deng L; Chen ZJ; Weichselbaum RR; Fu YX Immunity; 2017 Aug; 47(2):363-373.e5. PubMed ID: 28801234 [TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on. Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208 [TBL] [Abstract][Full Text] [Related]
9. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579 [TBL] [Abstract][Full Text] [Related]
10. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508 [TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
12. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362 [TBL] [Abstract][Full Text] [Related]
13. Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation. Piccio L; Vermi W; Boles KS; Fuchs A; Strader CA; Facchetti F; Cella M; Colonna M Blood; 2005 Mar; 105(6):2421-7. PubMed ID: 15383453 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Lo J; Lau EY; So FT; Lu P; Chan VS; Cheung VC; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK Liver Int; 2016 May; 36(5):737-45. PubMed ID: 26351778 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Chao MP; Alizadeh AA; Tang C; Jan M; Weissman-Tsukamoto R; Zhao F; Park CY; Weissman IL; Majeti R Cancer Res; 2011 Feb; 71(4):1374-84. PubMed ID: 21177380 [TBL] [Abstract][Full Text] [Related]
16. Anticancer drugs: Cracking the combination. Bordon Y Nat Rev Drug Discov; 2013 Jul; 12(7):505. PubMed ID: 23812266 [No Abstract] [Full Text] [Related]